339 results about "Steroid hormone" patented technology

The present invention relates to methods and kits for reducing the occurrence of preterm delivery and other pregnancy-related conditions in pregnant female subjects exhibiting one or more risk factors for preterm delivery and other pregnancy-related conditions. For example, the present invention relates to methods for reducing the occurrence of preterm delivery in a pregnant female subject having no history of preterm delivery and exhibiting one or more risk factors for preterm delivery (e.g., smoking during pregnancy). The methods and kits provide for the administration of a steroid hormone to the pregnant female subject.

The decomposer film product has a polymeric decomposer layer, a cover layer for protecting the decomposer film from the surroundings and a releasable support liner, which is removed prior to use. The polymeric decomposer film contains a water-soluble or water-insoluble polymeric adhesive material and a decomposition accelerator, which acts to decompose an effective ingredient, such as a steroid hormone, of a worn or unused transderamal patch, when the effective ingredient releasing layer of the patch adheres to the polymer film, so that the pharmaceutical effective ingredient comes into contact with the decomposition accelerator by diffusion. The decomposition accelerator includes a chemically oxidizing substance, preferably urea peroxide, manganese (III) acetate or iron (III) citrate. The water-insoluble polymeric adhesive material is preferably an acrylates adhesive. The water-soluble polymeric adhesive material is preferably polyvinyl alcohol, polyvinyl pyrrolidone, a cellulose derivative or a polyacrylic acid.

The invention relates to methods and pharmaceutical compositions for inhibiting or preventing preterm birth, inhibiting or delaying cervical ripening, inhibiting myometrial contractility and treating or inhibiting uterine contractility disorders. The methods comprise administering an effective amount of a composition comprising steroid hormones such as soluble progesterone.

Methods, systems and kits for the simultaneous or sequential analysis of a multitude of steroid hormones by mass spectrometry are disclosed. The methods require minimal sample size and minimal preparation time. The methods include ionizing the hormones and analyzing the hormones by mass spectrometry. In addition, methods, systems and kits for the simultaneous or sequential analysis of steroid hormones are disclosed including ionization of the steroid hormones by photoionization.

Highly concentrated drug particle formulations are described, wherein the drug comprises between about 25 wt % and 80 wt % of the particle formulation. The particle formulations of the present invention comprise, for example, macromolecules, such as proteins and / or small molecules (such as steroid hormones). The particle formulation typically further includes one or more additional component, for example, one or more stabilizer (e.g., carbohydrates, antioxidants, amino acids, and buffers). Such concentrated particle formulations can be combined with a suspension vehicle to form suspension formulations. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a highly concentrated drug particle formulation. Devices for delivering the suspension formulations and methods of use are also described. The present invention provides needed improvements in drug formulation and delivery to improve patient compliance and expand drug availability.

The present invention relates to steroid hormone products, such as oral contraceptive products, including at least one steroid active ingredient mixed with an excipient and having improved dissolution and release rate properties. The invention further relates to methods for making such steroid hormone products, wherein a mixture of the hormone and the excipient is subjected to sufficient mechanical energy to form a powder blend wherein the hormone is stabilized by the excipient in substantially non-crystalline form.

An agent for treating various kinds of diseases which contains at least one selected from the group consisting of sexual steroid hormone such as estrogen or its metabolites, its derivative, structural analogues thereof, estrogen acting substance or SERM non-feminizing estrogen (non-hormonal estrogen), and an activator of sirtuin and has a form of eye drops or eye washes, oral preparation, etc. An agent for treating eye diseases which has excellent treatment effects, reduced in side action can be provided.

The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, more particularly, Th1-mediated (cell-mediated) autoimmune diseases including: multiple sclerosis (MS), rheumatoid arthritis (RA), autoimmune thyroiditis and uveitis. Most preferably the invention is used to treat a patient with a therapeutically effective amount of estriol of 8 milligrams once daily via oral administration to treat the symptoms or prevent the onset of multiple sclerosis.

The invention relates to a film coating agent containing steroid hormone, which comprises 1 part of steroid hormone medicament, 1-50 parts of film forming materials, 0.5-10 parts of plasticizer, 0.5-10 parts of biological adhesive materials and 1-50 volumes of transdermal enhancer. The preparation of the present invention is capable of raising the efficiency of conveying steroid hormone medicament into the body by permeating skin and improving the irritation to the skin, and has good survivability. The invention also relates to a preparation method of the film coating agent, and the preparation method has the advantages of simple process, convenient operation and less energy consumption.

The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, neurodegenerative diseases or disorders, such as Alzheimer's disease, Parkinson's Disease, multiple sclerosis, stroke, ALS Pick's disease, prion disease and Huntington's disease. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of the diseases and disorders.

The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, neurodegenerative diseases or disorders, such as Alzheimer's disease, Parkinson's Disease, multiple sclerosis, stroke, ALS Pick's disease, prion disease and Huntington's disease. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of the diseases and disorders.

The present invention provides a method and composition for treatment of benign prostate hyperplasia (BPH) in men via a transscrotal delivery system. The composition of the present invention includes the steroid hormone progesterone containing permeation enhancers that greatly facilitate permeation through the skin, thus preventing modification of the constituents therein and providing continuous and sustained delivery of progesterone for several hours that mimics the circadian rhythm of endogenous progesterone. The progesterone composition preferably is capable of delivering an effective dosage amount of about 65-100 mg of progesterone per ml when applied directly onto the surface of scrotum.

The present invention relates to novel substituted steroid derivatives which represent selectiv inhibitors of the 17β-hydroxysteroid dehydrogenase type I (17β-HSD1) and, in addition, which may represent inhibitors of the steroid sulphatase, as well as to their salts, to pharmaceutical preparations containing these compounds and to processes for the preparation of these compounds. Furthermore, the invention concerns the therapeutic use of said novel substituted steroid derivatives, particularly their use in the treatment, inhibition, prophylaxis or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17β-hydroxysteroid dehydrogenase type I and / or steroid sulphatase enzymes and / or requiring the lowering of the endogenous 17β-estradiol concentration.

Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.

Disclosed is a conjugate comprising a biologically active agent (drug) linked to a subcellular targeting moiety that targets a drug specifically to the nucleus. Targeting is achieved by attaching a steroid hormone (or an analog) to the drug. The steroid hormone attached to the drug binds its corresponding receptor, the formation of the receptor-ligand complex results in the internalization of the complex into the nucleus, thus resulting in nuclear translocation of the drug. Also disclosed is a conjugate (comprising the complex of the drug and the steroid hormone) bound to a polymer by spacers allowing for concurrent passive targeting to the tumor cell (afforded by attachment to the polymer by the EPR effect) and nuclear targeting of the conjugate (due to the presence of the steroid). Using a suitable degradable spacer allows for the release of free drug in the tumor and enhances nuclear targeting efficacy. The polymer can be further linked to a cellular targeting molecule, where the targeting molecule directs the polymer to specific cells. One may thus be able to effectively target drugs to the nucleus of tumor cells. With little or modifications, several therapeutic agents can be targeted using the invention.

The present invention relates to methods of treating steroid hormone related disorders by modulating steroid hormone activity.

The invention relates to a preparation method of a steroid hormone medicinal intermediate, in particular to a preparation method for a betamethasone intermediate or its analogue. The betamethasone intermediate or its analogue is prepared from a compound I by means of elimination reaction, methylation reaction, cyano-group substitution reaction, siloxy protective reaction, intramolecular nucleophilic substitution reaction and esterification reaction. The method provided by the invention has the characteristics of cheap raw materials, and high and stable yield. The reaction route is as the following, wherein R1 is Cl or Br, and R is H or hydrocarbonyl of C1-C10.

The invention relates to 17-HPC pulmonary formulations for administration by inhalation comprising 17-HPC and a pharmaceutically acceptable excipient. Particle size reduction of 17-HPC is required for the pulmonary delivery, and can be achieved with a surfactant or water without the surfactant. Preferred pulmonary formulations include a powder blend comprising a therapeutically effective amount of at least one steroid hormone (progestogen) as a glucocorticoid sensitizer, and at least one pharmaceutically acceptable excipient, wherein the at least one steroid hormone (progestogen) has a particle size distribution profile ranging from about one nanometer to about ten microns in the powder blend.

3,15-substituted estrone compounds which act as inhibitors of 17β-hydroxysteroid dehydrogenase type I (17β-HSD1), salts thereof, pharmaceutical preparations containing such compounds, processes for preparing such compounds, and therapeutic uses of such compounds, particularly in the treatment or inhibition of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17β-hydroxysteroid dehydrogenase type I enzymes and / or requiring the lowering of the endogenous 17β-estradiol concentration, as well as the general use of selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors which possess in addition no or only pure antagonistic binding affinities to the estrogen receptor for the treatment or inhibition of benign gynecological disorders, particularly endometriosis.

A method of sexual enhancement in women includes the steps of identifying a woman requesting sexual enhancement, assuring that the woman's blood includes estradiol within a first predetermined range and testosterone within a second predetermined range, and thereafter administrating a drug selected from the group consisting of vardenafil hydrochloride and tadalafil prior to sexual activity. The selected drug may be loaded into a starch strip which is then applied to the woman's tongue. Sexual enhancement in women can also be achieved by transdermal or subcutaneous application of the steroid hormone DHEA.

The invention discloses a monolithic column, a preparation method and a application thereof. The preparation method comprises the following steps: 1) polymeric monomer, pore-foaming agent, initiator and cuprous bromide are mixed together and then added with catalyst ligand after being deoxidized; the mixture is put into a chromatographic column tube to react in a sealing way; after the reaction, the chromatographic column tube is connected with a high pressure transfer pump, and the soluble substances such as the pore-foaming agent and the like are rinsed and removed by organic solvent, so that a monolithic column with a three-dimensional continuous skeleton structure is obtained; 2) the mixture of the organic solution, catalyst, catalyst ligand and antioxidant of the functional monomer is injected into the monolithic column, and bromine group remained on the surface of the column body initiates the surface grafting polymerization reaction of vinyl monomer. The method leads polymerization reaction to be carried out at the room temperature, so as to greatly solves the problems of inhomogeneous column body structure, volume contraction and the like caused by high polymerization temperature. Compared with the traditional monolithic column, the obtained monolithic column has obviously different structure, thus being applicable to separating biological macromolecules such as steroid hormone drugs, protein or the like.

The invention discloses a method for producing an important steroid hormone dexamethasone methyl tetraenes (5ST) intermediate, which comprises the following steps of: dissolving a methyl dehydrate into an organic solvent, adding a reducing agent into the solution at the temperature of between 5 DEG C below zero and 20 DEG C, and performing one-step reaction to obtain methyl tetraenes with less than 0.8 percent of single impurity, wherein the reducing agent is a mixed reducing agent of 1 to 15 weight parts of chromium trichloride and 0.2 to 8 weight parts of zinc powder. The method for producing the 5ST shortens the reduction reaction into one-step reaction from three-step reaction so as to save the reaction time and facilitate the operation. The method reduces the consumption of chemical raw materials and dangerous goods, reduces the environmental pollution, and reflects the environment-friendly idea of green chemistry.

Substituted estratriene compounds of formula (I) useful in therapy, especially in the treatment or inhibition of a steroid hormone dependent disorder requiring the inhibition of a 17β-hydroxysteroid dehydrogenase (17β-HSD) type 1, type 2 and / or type 3 enzyme, as well as their salts, pharmaceutical compositions containing such compounds and processes for preparing such compounds.

The invention relates to a temperature-sensitive in-situ gel preparation composition for intra-articular injection and a preparation method thereof, and belongs to the field of medicine preparations. The preparation method comprises the following steps: preparing diclofenac sodium-carrying sodium alginate microspheres by combining a microsphere technology with a temperature-sensitive gel technology, and then carrying the medicine-carrying microspheres in a chitosan / beta-sodium glycerophosphate temperature-sensitive in-situ gel system to obtain a diclofenac sodium in-situ gel preparation composition. The composition is in a liquid state at a room temperature, capable of being converted to a semi-solid gel at a body temperature and forming a medicine storeroom at a medication part after being partially injected to enter an articular cavity, and beneficial to slowly releasing the medicine, prolonging the time of staying at the injection part, of the medicine, and enhancing the efficacy. The composition disclosed by the invention can be used for treating arthritis diseases of rheumatism, rheumatoid arthritis, osteoarthritis, synovitis and the like, as well as applicable to both diclofenac sodium and other arthritis treatment medicines of non-steroidal anti-inflammatory medicines, steroid hormone medicines, biological preparations and the like.

The invention provides a method for simultaneously detecting 13 kinds of steroid hormones in serum. The method includes the following steps: a to-be-tested serum sample is mixed with an internal standard solution, a detection liquid is obtained by liquid-liquid extraction, and detection is performed by ultra-high-performance liquid chromatography-tandem mass spectrometry; liquid chromatography conditions are that: a mobile phase A is a formic acid aqueous solution of 0.1%, and a mobile phase B is a formic acid methanol solution of 0.1%; mass spectrometry conditions are that: a positive ion mode employs a multi-reaction monitoring mass spectrometry scanning mode; and the 13 kinds of steroid hormones include pregnenolone, progesterone, 17-hydroxypregnenolone, 17[alpha]-hydroxyprogesterone, 11[alpha]-hydroxyprogesterone, 21-deoxycortisol, 11-deoxycorticosterone, corticosterone, cortisol, 11-deoxycortisol, cortisone, aldosterone, and estrone. The method simultaneously detects the 13 kindsof steroid hormones with the detection time of only 6 minutes, and is easy to operate and takes less time; the sensitivity is high, the accuracy is good, the specificity is strong, a detection range is wide, and an application prospect in medical and biochemical detection fields is broad.

The invention provides a preparation method for hydroxylation of 11 alpha of an important intermediate of a steroidal hormone substance, and aims to solve the problems that the conversion rate is low and the environment is polluted when a microorganism is used for converting steroidal C11 alpha for hydroxylation in the prior art. The preparation method comprises the following steps: strain breeding, wherein a strain of ochratoxin or rhizopus nigricans is inoculated to a corresponding seed medium for cultivation; substrate emulsification, wherein a substrate selected from one of 17-alpha hydroxyl progesterone, 4-androstenedione or 16,17-alpha epoxy progesterone is subjected to emulsification treatment under the action of a surfactant; fermented cultivation, wherein the ochratoxin or rhizopus nigricans is inoculated to a fermented medium to be cultivated for a period of time, and then one of emulsion liquids of sterilized 17-alpha hydroxyl progesterone, 4-androstenedione or 16,17-alpha epoxy progesterone is added for performing continuous fermented cultivation; extracting a finished product. The method has the advantages of high conversion rate, little pollution, environmental protection, low pressure and the like.

The present disclosure provides for compositions and methods of stimulating reproductive behavior and reproductive success and productivity in a suid, such as pigs. The composition may comprise at least one steroid hormone and a heterocyclic aromatic compound. The method comprises administering the pheromone composition to the suid for a period of time.

The present invention relates to a method for environment-protecting pollutionless production of diosgenin. Before the steps of extraction, concentration and crystallization of conventional method the steps of raw material pretreatment, sieving, membrane filtering and dewatering, fermentation, hydrolysis, filtration, secondary hydrolysis and water-washing are successively implemented or the steps of raw material pretreatment, sieving, membrane filtering and dewatering, adding solvent to make extraction separation to twice, combining extracts, distilling, fermentation and hydrolysis are successively implemented. It has no need of complex special equipment, and can purify and produce diosgenin as basic raw material of steroid hormone medicine by utilizing diascorea plant.

The present invention is directed to methods, pharmaceutical compositions and kits for modulating skeletal muscle precursor cell activation. Modulation is effected through the use of nitric oxide (NO), donors of NO, inhibitors of NO activity (NO inhibitor) or regulators of NO production, either locally or systemically. The invention further teaches the use of NO, an NO donor, an NO inhibitor or a regulator of NO production to modulate the effects of steroid hormone on skeletal muscle. The invention further provides a method for identifying a compound which effects a change in activation state of muscle precursor cells. A number of advantages is evident. By allowing skeletal muscle precursor cells to be manipulated directly, the invention enables specific treatments to regenerate and repair muscle.